No Data
Express News | Jiangsu Kanion Pharmaceutical: KYS0.202 million A injection has received clinical trial approval.
China Approves Jiangsu Kanion Pharmaceutical's Clinical Trial for Psoriasis Cream
Express News | Jiangsu Kanion Pharmaceutical: received the clinical trial approval notice for KYHY2303 tablets.
The new acquisition plan of jiangsu kanion pharmaceutical sees the valuation of intangible assets skyrocket. Who benefits and who compromises?
0.7895 million yuan of intangible assets assessed at 0.63 billion yuan. On November 25, Cai Jun of Investors.com reported that Jiangsu Kanion Pharmaceutical (600557.SH, hereinafter referred to as the 'Company') announced the adjustment plan for asset acquisition and the regulatory reply letter to the Shanghai Stock Exchange. In this round of acquisition, the Company not only involves the injection of assets by major shareholders across different tracks, but also attracts widespread attention from investors due to high valuation and transaction settings. In the new plan, the Company made adjustments to the handling of equity and debt, with various negotiations and compromises taking place. The sharp rise in the valuation of intangible assets, according to the announcement, Jiangsu Kanion Pharmaceutical plans to use its own funds to acquire 100% equity of the CSI Health Care 100 Index for 0.27 billion yuan.
US FDA Approves Kanion Pharma's Clinical Trial for Psoriasis Injection
Express News | Nearly 20 A-share listed companies disclosed the latest M&A restructuring announcements this week. Western Securities intends to acquire 64.6% stake in Guorong Securities for 3.825 billion yuan.
No Data
No Data